Tagged with access,

USA Take our poll on Donald Trump and Pharma at the bottom of the article Speaking at a White House meeting with senior pharmaceutical executives, US President Donald Trump told drug companies to lower their “astronomical” prices. He pledged to curb regulations and lower tax rates to allow companies to do so,…

Switzerland Not all impactful innovation involves the development of new chemical or biological entities, and the value of such innovation must be recognized in pricing processes argues Gebro Pharma Switzerland CEO Marcel Plattner. We understand you serve as the head of the executive committee for market access and pricing within the…

Switzerland Frederic Bengold, MD of Servier Switzerland, on the affiliate’s main growth drivers, an exciting collaboration with Novartis on heart failure medication, and the intricacies of market access in Switzerland. Could you please start by introducing Servier’s Swiss affiliate? We enjoy a longstanding presence and reputation in Switzerland. The local affiliate…

Slovakia Pharma companies in Slovakia are managing to circumvent the problems inherent in the size of the local market by focusing on the country’s advantages in market access and regional leadership, as well as through joining together with affiliates in neighboring Czech Republic. “Slovakia is a developed and established EUR 1.25…

Switzerland Specializing in ultra-rare diseases, Alexion targets patient populations of less than 20 patients per million. Christophe Bourdon discusses Alexion’s progress towards developing access for patients across the EMEA region.   Since day one, Alexion’s mission has been to focus solely on discovering treatments for patients affected by these incredibly rare…

Slovakia Biogen Slovakia’s Country Director on being an innovative global biotech in Slovakia, market access in the country, and the company’s commitment to improving the lives of patients through MS, Alzheimer’s and rare disease treatments. Ms. Strapkova Boydova, you have been Country Director of Biogen Slovakia since its inception in 2006.…

Mexico Alvaro Angel, the recently appointed general manager of the pharmaceutical division of Bayer Mexico, provides insights into the rapidly evolving local pharma market, and documents Bayer Mexico’s ambitious growth strategy; with the affiliate already standing out as one of the most important of the group at a global level. You…

Slovakia Lundbeck Slovakia Country Manager, Svatopluk Betina, reflects on the performance of one of the most innovative pharmaceutical firms in the region and the challenges companies face when introducing new products to the market Can you please provide an overview of Lundbeck’s presence in Slovakia and share with our audience the…

Slovakia Dr. Leonard Sojka who has spent over 25 years with the innovation-driven Merck group explains how Merck is turning its focus to science and technology; his experience on market access; the specificities of the Slovak market; and why Merck is a great company to work for. 2015-16 has been a…

Slovakia Dr. Natasa Klicko, General Manager of Roche Slovakia, outlines the challenges and opportunities for the company in the country; their strategy of going “beyond the pill” to partner with and provide value to all healthcare stakeholders; the importance of data and methodology in the debate on market access; and Slovakia…

Luxembourg The recently appointed managing director of Pfizer Luxembourg discusses the current footprint of the company in the country; how every affiliate within the group counts; market access procedures; and the role of Luxembourg within the life sciences and healthcare sector. Since September 2016, you have been managing director of Pfizer…

Switzerland As the home market, Switzerland and Roche’s Swiss pharma operations play an important and pioneering role within Roche’s global organization, with early patient access to innovation and new commercial models taking place in the country. The working title of the Healthcare & Life Science Review Switzerland is “A Leader Among…